HOOKIPA Pharma Inc.

HOOK

US43906K1007

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 24/05/2024 am IST			5-day change	1st Jan Change
1.04 ^USD	+6.12%		+28.24%	+28.40%

09/05	HOOKIPA Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
25/04	Transcript : HOOKIPA Pharma Inc. - Special Call

HOOKIPA Pharma Inc. Appoints Jean-Charles Soria to its Board of Directors

October 19, 2020 at 05:30 pm IST

HOOKIPA Pharma Inc. announced the appointment of Jean-Charles Soria to its Board of Directors. Jean-Charles Soria is currently serves as Director General of the Gustave Roussy Cancer Center.

Latest news about HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Transcript : HOOKIPA Pharma Inc. - Special Call	25/04
HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab	25/04	CI
HOOKIPA Pharma Inc. Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers	24/04	CI
HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200	10/04	CI
HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
HOOKIPA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/03	CI
North American Morning Briefing : Stocks Struggle After New Records	22/03	DJ
North American Morning Briefing : Stock Futures -2-	13/03	DJ
RBC Cuts Price Target on HOOKIPA Pharma to $5 From $6 Amid Restructuring Plan, Termination of Roche Partnership on KRAS; Outperform, Speculative Risk Kept	30/01	MT
HOOKIPA Pharma to Cut 30% of Workforce in Restructuring	29/01	MT
HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024	16/01	CI
Top Premarket Gainers	21/12	MT
HOOKIPA Pharma Inc. announced that it has received $21.2505 million in funding from Gilead Sciences, Inc.	20/12	CI
HOOKIPA Pharma Inc. Announces Appointment of Dr. Roman Necina as Chief Operations Officer, Effective January 1, 2024	02/12	CI
HOOKIPA Pharma's HIV Vaccine Candidate HB-500 Receives FDA Clearance for Investigational New-Drug Application	20/11	MT
Hookipa Pharma Announces FDA Clearance of Its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus	20/11	CI
HOOKIPA Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
HOOKIPA Pharma Inc. Presents Positive Biomarker and Translational Data on HB-200 Monotherapy At Society for Immunotherapy of Cancer 2023	03/11	CI
HOOKIPA Pharma Says Head, Neck Cancer Phase 2 Study of Therapy Combination Showed 42% Objective Response Rate	23/23/23	MT
Hookipa Pharma Inc. Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023	22/23/22	CI
HOOKIPA Pharma Operations Chief Christine Baker Resigns	21/23/21	MT
HOOKIPA Pharma Inc. Announces Resignation of Christine Baker as Chief Operating Officer, Leaving on January 15, 2024	21/23/21	CI
HOOKIPA Pharma Inc. Announces Publication of Preclinical Data of Hepatitis B Virus Therapeutic Vaccine Developed in Collaboration with Gilead Sciences	18/23/18	CI
HOOKIPA Pharma Inc. Announces Management Changes	13/23/13	CI

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Companyâs replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Sector

Pharmaceuticals

Calendar

03/06/2024 - American Society of Clinical Oncology Annual Meeting - Abstract No.: 6017

More about the company

Income Statement Evolution

More financial data

Ratings for HOOKIPA Pharma Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.04 USD

Average target price

4.6 USD

Spread / Average Target

+342.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HOOKIPA PHARMA INC.	+28.40%	103M
ELI LILLY AND COMPANY	+38.69%	728B
NOVO NORDISK A/S	+34.28%	603B
JOHNSON & JOHNSON	-4.49%	360B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	279B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	207B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	163B

Other Pharmaceuticals